Log In | Register
"Safe is clearly better than sorry," he told the ADA audience, agreeing on the advantage of having more data on cardiovascular outcomes at the time of drug approval.
After 50 years in the dark, ADA calls for well-designed, adequately-powered comparative effectiveness trials on macrovascular outcomes in type 2 diabetes (not fair to kill people)
Seeded on Mon Jun 28, 2010 12:12 PM EDT
Article Source: Medpage Today- Enjoy this article? Help vote it up the 'Vine.
- Public Discussion (1)
'Because cardiovascular disease is the cause of death in roughly 75% of diabetes patients, "knowing what the effect of the drug is going to be in that population in cardiovascular outcome is essential,"
They just figured that out after how many deaths? After making how many billions?
- 2 votes
#1 - Mon Jun 28, 2010 12:13 PM EDTYou're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.
